{
  "ptid_time": "072_S_4102_2011-10-24",
  "img_path": "/data/qiuhui/data/adni/images/072_S_4102/2011-10-24/t1.nii.gz",
  "img_finding": "Image findings: ventricular volume measures 65,493 mm³, 193.2% above the reference mean. With a Z-score of 4.84 (100.0th percentile), this represents profound enlargement; hippocampal volume measures 5,491 mm³, 28.5% below the reference mean. With a Z-score of -3.20 (0.1th percentile), this represents profound atrophy; whole brain volume measures 1,003,550 mm³, 2.5% below the reference mean. With a Z-score of -0.31 (37.8th percentile), this represents normal volume ; entorhinal cortex volume measures 2,186 mm³, 43.8% below the reference mean. With a Z-score of -3.40 (0.0th percentile), this represents profound atrophy; fusiform gyrus volume measures 15,840 mm³, 13.0% below the reference mean. With a Z-score of -1.47 (7.1th percentile), this represents mild atrophy; middle temporal gyrus volume measures 12,213 mm³, 40.5% below the reference mean. With a Z-score of -3.60 (0.0th percentile), this represents profound atrophy. ",
  "text_data": "Age is 66.9 years. Gender is Female. Education: 14 years. Handedness: Right. Race: White. Medical history: Psychiatric; Head, Eyes, Ears, Nose and Throat; Gastrointestinal. MMSE: 30.0. MoCA: 18.0. Logical Memory: 6.0. Laboratory findings: Creatine Kinase: 290.00 (profound elevated). APOEε4 alleles: 0.0. Biomarker levels: Florbetapir (AV45): 1.00 SUVR (normal ); Amyloid beta: 1101.00 pg/mL (normal ); Total tau: 176.70 pg/mL (normal ); Phosphorylated tau: 11.53 pg/mL (mild reduced). ",
  "true_diagnosis": "Diagnosis: MCI.",
  "gpt_diagnosis": "**Reasoning:** The imaging data shows profound atrophy in key Alzheimer's-related regions (hippocampus, entorhinal cortex, middle temporal gyrus) alongside severe ventricular enlargement, strongly suggestive of neurodegeneration. Despite normal Aβ and MMSE (30), the MoCA score (18) indicates significant cognitive impairment, likely due to non-amyloid pathology (e.g., primary tauopathy or hippocampal sclerosis).  \n\n**Diagnosis:** **Dementia** (likely non-AD subtype, e.g., limbic-predominant age-related TDP-43 encephalopathy [LATE] or primary age-related tauopathy [PART]).  \n\n**Confidence:** **Medium** (high confidence in neurodegeneration/dementia, but low confidence in specific etiology due to normal biomarkers).  \n\n**Key points:**  \n- **Mismatch:** Normal Aβ but profound atrophy suggests non-AD pathology.  \n- **MoCA vs. MMSE:** MMSE is insensitive to early/mild deficits; MoCA 18 is dementia-range.  \n- **APOE4-negative:** Supports non-AD etiology (e.g., TDP-43 or PART).  \n- **Next steps:** Consider FDG-PET (temporal hypometabolism?) or TDP-43/tau biomarkers if available.",
  "timestamp": "2025-07-26T09:16:57.376300"
}